{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T03:25:43.932515+00:00","company":{"ticker":"MAIA","cik":1878313,"company_name":"MAIA Biotechnology, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"38b6f16b1c0554c286bf12929ada47d49e8c093b","cik":1878313,"ticker":"MAIA","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC","effective_date":"2026-03-02","item_codes_triggered":["1.01"],"value_text":"approximately $30.0 million"},"claim":"MAIA Biotechnology, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at approximately $30.0 million (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-008897","anchor_url":"https://secwatch.observer/filing/0001493152-26-008897#claim-38b6f16b1c0554c286bf12929ada47d49e8c093b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226008897/0001493152-26-008897-index.htm"},{"fact_type":"material_agreement","fact_key":"f2d75c5f3bdfa14038d80f77993c0813775fafc5","cik":1878313,"ticker":"MAIA","company_name":"MAIA Biotechnology, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"\"Purchase Agreement\"","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2024-04-22","item_codes_triggered":["1.01"],"value_text":"aggregate purchase price of approximately $664,994"},"claim":"MAIA Biotechnology, Inc. entered into \"Purchase Agreement\" with certain accredited investors valued at aggregate purchase price of approximately $664,994 (effective 2024-04-22).","evidence_excerpt":"On April 22, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 326,939 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-106975","anchor_url":"https://secwatch.observer/filing/0001193125-24-106975#claim-f2d75c5f3bdfa14038d80f77993c0813775fafc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/0001193125-24-106975-index.htm"}]}